Ablynx is developing a nanobody-based portfolio of therapeutics in a number of therapeutic areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development.
Ablynx has exclusive rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.
Ablynx is expected to lease 8,000m(2) of the brand new 10,000m(2) building which is located on the same Technologiepark as the former facilities of Ablynx.
Edwin Moses, CEO and chairman of Ablynx, said: “This new laboratory building is expected to support Ablynx’s growth in the future. This allows us to house our Belgian operations in one facility.”